文献速递免疫规划传染病防控与疫情报告

既往接种鼠脑来源日本脑炎疫苗的成人单剂Vero细胞培养疫苗后12-23个月免疫应答

Immune response at 12-23 months following a single dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine.
PubMed 文献 · Vaccine · 2020-09-06

本研究评估既往接种过鼠脑来源日本脑炎疫苗(JE-MB)的成人,在接种单剂Vero细胞培养日本脑炎疫苗(JE-VC)后12-23个月的中和抗体应答是否非劣效于未接种过日本脑炎疫苗的成人完成两剂JE-VC基础免疫后的应答。结果显示既往接种组几何平均滴度(GMT)为75(95%CI 63-90),未接种组为12(95%CI 11-14),血清保护率分别为94%(235/250)和54%(135/250),GMT比值为6.3(95%CI 5.0-7.7),满足非劣效标准。结论认为单剂JE-VC可为既往接种JE-MB者提供至少1-2年的良好保护。

要点

  • 既往接种JE-MB的成人单剂JE-VC后12-23个月GMT为75,未接种组两剂后GMT为12。
  • 血清保护率分别为94%(235/250)和54%(135/250),GMT比值6.3(95%CI 5.0-7.7)满足非劣效。
  • 单剂JE-VC可为既往接种JE-MB的成人提供至少1-2年的良好保护。

核心结论

  • 既往接种JE-MB的军人在单剂JE-VC后12-23个月的中和抗体应答非劣效于未接种者完成两剂JE-VC基础免疫后的应答。
  • 单剂JE-VC可为既往接种JE-MB的成人提供至少1-2年的良好保护。

研究设计与样本

  • 获取美国军人存档血清,采用50%斑块减少中和试验检测抗日本脑炎病毒中和抗体。
  • 比较既往接种JE-MB者单剂JE-VC后与未接种者第二剂JE-VC后12-23个月的GMT和血清保护率。
  • 非劣效标准为既往接种组与未接种组GMT比值的双侧95%CI下限>1/1.5。

主要发现

  • 既往接种JE-MB者GMT为75(95%CI 63-90),未接种者GMT为12(95%CI 11-14)。
  • 血清保护率分别为94%(235/250)和54%(135/250)。
  • GMT比值为6.3(95%CI 5.0-7.7),满足非劣效标准。

关键数值与推荐

  • 非劣效判定标准:GMT比值的双侧95%CI下限>1/1.5。
  • 既往接种组GMT 75(95%CI 63-90),未接种组GMT 12(95%CI 11-14)。
  • 血清保护率94%(235/250) vs 54%(135/250)。
  • GMT比值6.3(95%CI 5.0-7.7)。

临床怎么用

  • 对于既往接种过JE-MB的成人旅行者,出行前可接种单剂JE-VC以完成再免疫。
  • 单剂JE-VC方案可缩短再免疫完成时间、降低不良事件风险并减少成本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Japanese encephalitis (JE) virus is an important cause of neurological disease in Asia. JE vaccine is recommended for travelers with higher JE risk itineraries. Inactivated Vero cell culture-derived JE vaccine (JE-VC) is the only JE vaccine currently available in the United States. An inactivated mouse brain-derived JE vaccine (JE-MB) previously was available but production was discontinued. One JE-VC dose administered to adults previously vaccinated with ≥3 doses of JE-MB provides good short-term protection for at least one month, but data on longer-term protection are limited. We evaluated non-inferiority of the JE virus neutralizing antibody response at 12-23 months in JE-MB-vaccinated adults administered one JE-VC dose compared with JE vaccine-naïve adults administered a JE-VC two-dose primary series. METHODS: We obtained archived sera from U.S. military personnel and performed a 50% plaque reduction neutralization test for anti-JE virus neutralizing antibodies. We compared the geometric mean titer (GMT) and seroprotection rate at 12-23 months after one JE-VC dose in previously JE-MB-vaccinated personnel and after the second JE-VC dose in previously JE vaccine-naïve personnel. Non-inferiority was concluded if the lower bound of the two-sided 95% confidence interval (CI) of the GMT ratio in previously vaccinated to vaccine-naïve personnel was >1/1.5. RESULTS: The GMT in previously JE-MB-vaccinated persons was 75 (95% CI 63-90) and in previously JE vaccine-naïve persons was 12 (95% CI 11-14), and seroprotection rates were 94% (235/250) and 54% (135/250), respectively. The ratio of GMTs was 6.3 (95% CI: 5.0-7.7), satisfying the criterion for non-inferiority. CONCLUSIONS: One JE-VC dose in previously JE-MB-vaccinated military personnel provides good protection for at least 1-2 years. The benefits of administration of a single JE-VC dose in previously JE-MB-vaccinated adults include a shorter time to completion of re-vaccination before travel, a decrease in the risk of adverse events, and reduced costs.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Krow-Lucal ER, Laven J, Perry L, et al. Immune response at 12-23 months following a single dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine. Vaccine. 2020. PMID: 32907756. doi:10.1016/j.vaccine.2020.08.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。